002252.SZ
002252.SZ
CNE100000C31
SHANGHAI RAAS
Loading chart...

Company Profile

Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product. It also provides specific immune, human tetanus immunoglobulin, human rabies immunoglobulin, human immunoglobulin, hepatitis B human immunoglobulin, and other blood products. The company exports its products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is headquartered in Shanghai, China.

Related stocks

688336.SS
688336.SS • China
SUNSHINE GUOJIAN PHARMACEUTICAL
38.1 CNY
5.11B USD 1Y +4.2%
1530.HK
1530.HK • China
3SBIO
15.07 HKD
4.76B USD 1Y -47.3%
300122.SZ
300122.SZ • China
ZHIFEI-BIOL
13.7 CNY
4.91B USD 1Y -34.6%
9995.HK
9995.HK • China
REMEGEN
70.4 HKD
5.34B USD 1Y -33.7%
600161.SS
600161.SS • China
BEIJING TIANTAN BIOLOGICAL PROD
12.73 CNY
3.77B USD 1Y -34%
688180.SS
688180.SS • China
SHANGHAI JUNSHI BIOSCIENCES CO
33.83 CNY
5.19B USD 1Y -17.6%
002007.SZ
002007.SZ • China
HUALAN BIO.
13.35 CNY
3.65B USD 1Y -17.6%
6821.HK
6821.HK • China
ASYMCHEM
155.1 HKD
7.15B USD 1Y +60.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
24.1% p.a.
Max Drawdown (5Y)
-49.1%
Sharpe Ratio (5Y)
-0.35
Beta Factor
0.27
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (24.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -81.6% in the extended horizon.
ende